An NDM-Producing
PBP3
antimicrobial resistance
aztreonam
cefiderocol
ceftazidime-avibactam
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
10
02
2023
accepted:
15
05
2023
medline:
7
7
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
Cefiderocol and ceftazidime-avibactam plus aztreonam (CZA-ATM) are preferred treatment regimens for New Delhi metallo-β-lactamase (NDM)-producing infections. We report the case of a US patient who traveled to India to receive a renal transplant. He subsequently experienced pyelonephritis by an NDM-producing An This is the first clinical case of a US patient harboring an NDM-producing isolate exhibiting resistance to all available β-lactam agents. The isolate's unexpected resistance to cefiderocol and CZA-ATM was likely due to a combination of (1) a modified PBP3 (increased MICs to both regimens), (2) truncated iron-binding protein (increased cefiderocol MIC), and (3) a
Sections du résumé
Background
UNASSIGNED
Cefiderocol and ceftazidime-avibactam plus aztreonam (CZA-ATM) are preferred treatment regimens for New Delhi metallo-β-lactamase (NDM)-producing infections.
Methods
UNASSIGNED
We report the case of a US patient who traveled to India to receive a renal transplant. He subsequently experienced pyelonephritis by an NDM-producing
Results
UNASSIGNED
An
Conclusions
UNASSIGNED
This is the first clinical case of a US patient harboring an NDM-producing isolate exhibiting resistance to all available β-lactam agents. The isolate's unexpected resistance to cefiderocol and CZA-ATM was likely due to a combination of (1) a modified PBP3 (increased MICs to both regimens), (2) truncated iron-binding protein (increased cefiderocol MIC), and (3) a
Identifiants
pubmed: 37416757
doi: 10.1093/ofid/ofad276
pii: ofad276
pmc: PMC10319620
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad276Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. P.J.S. reports grants and personal fees from Accelerate Diagnostics, OpGen, Inc., and BD Diagnostics; grants from bioMerieux, Inc., Affinity Biosensors, and Hardy Diagnostics; and personal fees from Roche Diagnostics, Shionogi, Inc., GeneCapture, outside the submitted work. R.C. and S.B. are employees of Ares Genetics. All other authors have nothing to disclose.
Références
Lancet Infect Dis. 2011 May;11(5):355-62
pubmed: 21478057
Microbiol Spectr. 2021 Dec 22;9(3):e0177921
pubmed: 34756080
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0084621
pubmed: 34424044
Int J Antimicrob Agents. 2019 Feb;53(2):177-184
pubmed: 30395986
Microb Drug Resist. 2022 Feb;28(2):161-170
pubmed: 34619049
mSphere. 2020 Apr 29;5(2):
pubmed: 32350092
J Antimicrob Chemother. 2021 Mar 12;76(4):979-983
pubmed: 33367916
Clin Infect Dis. 2022 Aug 24;75(1):47-54
pubmed: 34618008
Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34
pubmed: 26574013
J Antimicrob Chemother. 2020 Jun 1;75(6):1650-1651
pubmed: 32040179
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30373801
Front Microbiol. 2022 Sep 15;13:959107
pubmed: 36187949
J Antimicrob Chemother. 2020 Mar 1;75(3):559-565
pubmed: 31722380
Infect Dis (Lond). 2020 Nov;52(11):801-807
pubmed: 32628575
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0031122
pubmed: 35867524
Antimicrob Agents Chemother. 1982 Jun;21(6):950-6
pubmed: 6180685
PLoS One. 2015 Apr 24;10(4):e0123337
pubmed: 25909482
Clin Infect Dis. 2022 Aug 25;75(2):187-212
pubmed: 35439291
Emerg Infect Dis. 2021 Oct;27(10):2628-2637
pubmed: 34545787
Infect Control Hosp Epidemiol. 2023 May;44(5):762-767
pubmed: 35822340
J Clin Microbiol. 2019 Jan 30;57(2):
pubmed: 30282791
J Antimicrob Chemother. 1995 Jul;36(1):53-64
pubmed: 8537284
Open Forum Infect Dis. 2020 Jan 21;7(2):ofaa011
pubmed: 32042848
Antimicrob Agents Chemother. 1991 Nov;35(11):2312-7
pubmed: 1804003
Epidemiol Infect. 2019 Jan;147:e137
pubmed: 30869056
Clin Infect Dis. 2022 Mar 9;74(5):905-908
pubmed: 34079986
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4364-8
pubmed: 27114282
J Clin Microbiol. 2021 Feb 18;59(3):
pubmed: 33361340
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0201121
pubmed: 34871093
Antimicrob Agents Chemother. 2008 Apr;52(4):1510-2
pubmed: 18250190
Antimicrob Agents Chemother. 2020 Nov 17;64(12):
pubmed: 32988825
Microbiol Spectr. 2022 Jun 29;10(3):e0267021
pubmed: 35481835
mSystems. 2020 Nov 3;5(6):
pubmed: 33144312
J Antibiot (Tokyo). 1990 Mar;43(3):314-20
pubmed: 2108953
J Antibiot (Tokyo). 2022 Aug;75(8):454-462
pubmed: 35715617
Diagn Microbiol Infect Dis. 2021 Jan;99(1):115227
pubmed: 33086177
Int J Antimicrob Agents. 2018 Nov;52(5):688-691
pubmed: 30044946
J Glob Antimicrob Resist. 2022 Sep;30:214-221
pubmed: 35760303
Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22002-7
pubmed: 21135211
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0048621
pubmed: 34060895
Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4
pubmed: 17470659
J Antimicrob Chemother. 2023 May 3;78(5):1191-1194
pubmed: 36921067
J Antimicrob Chemother. 2015 May;70(5):1420-8
pubmed: 25634992
Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2319-2327
pubmed: 28748397
Clin Microbiol Infect. 2000;6 Suppl 3:34-40
pubmed: 11449647
Antibiotics (Basel). 2022 Oct 04;11(10):
pubmed: 36290010
Clin Infect Dis. 2021 Jun 1;72(11):1871-1878
pubmed: 32427286
Antimicrob Agents Chemother. 2015 May;59(5):2785-90
pubmed: 25733506
Biomed Res Int. 2014;2014:249856
pubmed: 24790993
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28167541
Emerg Infect Dis. 2013 Jun;19(6):870-8
pubmed: 23731823
Antimicrob Agents Chemother. 2009 Dec;53(12):5046-54
pubmed: 19770275
J Clin Microbiol. 2023 May 23;61(5):e0164722
pubmed: 37070979
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29061741